TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00559845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin
Description: 90 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered at 80 mg/m\^2 i.v. over 1 hour weekly for 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered at 10 milligrams per kilogram (mg/kg) i.v. every 2 weeks for 6 cycles.
Study: NCT02421224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
Study: NCT02309879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate infusion
Description: Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate infusion
Description: Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate infusion
Description: Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate infusion
Description: Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate and Lidocaine infusion
Description: Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate and Lidocaine infusion
Description: Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate and Lidocaine infusion
Description: Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate and Lidocaine infusion
Description: Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
Study: NCT02618889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
Study: NCT03745170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
Study: NCT04219631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate.
Description: women enrolled in WINNER-FLOW-URO-MG group will freely use the expiratory mouthpiece device during all their childbirth process.
Study: NCT02950025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online, adaptive MR-guided SBRT
Description: Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
Study: NCT03745170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 Q3W on Day 1 by IV infusion
Study: NCT02950025

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online, non-adaptive MR-guided SBRT
Description: Patients will not have online-adaptive treatment planning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
Description: * 30 questions~* 28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~* 1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~* 1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
Description: * 30 questions~* 28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~* 1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~* 1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent
Study: NCT01373801

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The HemCon GuardaCare
Description: The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The HemCon GuardaCare
Description: The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard packing gauze roll bandage.
Study: NCT00066950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: 0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: 0.25ml FV every 6 months from age 12 to 30 months
Study: NCT01442233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasma exchange
Description: 6 plasma exchange each 48 hours during 2 weeks after randomization

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham exchanges procedure
Description: 6 sham exchanges each 48 hours during 2 weeks after randomization
Study: NCT01414114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
Study: NCT01737944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Vibex MTX Device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Vibex MTX Device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Vibex MTX Device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Vibex MTX Device
Study: NCT03745170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m\^2 Q3W on Day 1 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Study: NCT00002925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ara-C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ara-C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSC-833

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldesleukin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Study: NCT03787953

Intervention type: DRUG
Intervention: Anti-PD-1/PD-L1 antibodies
Description: The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
Study: NCT02046356

Intervention type: PROCEDURE
Intervention: MESS-RFA
Study: NCT00052208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00818233

Intervention type: DEVICE
Intervention: Dynamic contour tonometry
Description: Observe variability of measurements by dynamic contour tonometry
Study: NCT02562430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Welbutrin XL
Description: 12.5% of participants will receive Welbutrin XL in phase 1 of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 87.5% of subjects will be randomized to placebo in phase 1 of the study.
Study: NCT04519710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
Description: to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
Description: to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
Description: to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
Study: NCT02050360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01545284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
Study: NCT04528849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin dose increment timing
Description: Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin dose increment timing
Description: Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.
Study: NCT03589443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiplexed heptapeptides
Description: Heptapeptides QRH and KSP
Study: NCT03745170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
Study: NCT01244906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
Study: NCT03228667

Intervention type: DRUG
Group type: OTHER
Intervention: N-803 + Pembrolizumab
Description: Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
Study: NCT02421224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
Study: NCT02421224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposits
Description: Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
Study: NCT03228667

Intervention type: DRUG
Group type: OTHER
Intervention: N-803 + Pembrolizumab
Description: Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Pembrolizumab
Description: Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: N-803 + Nivolumab
Description: Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: N-803 + Nivolumab
Description: Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: N-803 + Nivolumab
Description: Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Nivolumab
Description: Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: N-803 + Atezolizumab
Description: Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
Study: NCT04245332

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Fish oil-derived omega-3 polyunsaturated fatty acids (4g fish oil concentrate: 2g EPA+ 1g DHA)
Study: NCT03228667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Atezolizumab
Description: Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: N-803 + Avelumab
Description: Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Avelumab
Description: Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: N-803 + Durvalumab
Description: Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Durvalumab
Description: Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Pembrolizumab + PD-L1 t-haNK
Description: Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Nivolumab + PD-L1 t-haNK
Description: Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Atezolizumab + PD-L1 t-haNK
Description: Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly